New pill hopes to slow deadly lung scarring
NCT ID NCT06325696
First seen Jan 18, 2026 · Last updated May 15, 2026 · Updated 20 times
Summary
This study tests an oral drug called H01 (hymecromone) in 37 adults with interstitial lung disease, a condition that causes lung scarring and often leads to death within 3-5 years. Participants take the drug twice daily for 12 weeks. The goal is to see if H01 can lower a marker of scarring in the blood and improve lung function.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NIEHS Clinical Research Unit (CRU)
RECRUITINGResearch Triangle Park, North Carolina, 27709, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.